186 results
Keyword Epinephrine Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Ruxience
rituximab, Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Microscopic Polyangiitis; Pemphigus
Date of authorisation: 01/04/2020,
, 
, Revision: 10, Authorised, Last updated: 13/12/2022
-
List item
Human medicine European public assessment report (EPAR): Azarga
brinzolamide, timolol maleate, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 25/11/2008, Revision: 16, Authorised, Last updated: 11/10/2022 -
List item
Human medicine European public assessment report (EPAR): Blitzima
rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017,, Revision: 18, Authorised, Last updated: 02/02/2023
-
List item
Human medicine European public assessment report (EPAR): Truxima
rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Wegener Granulomatosis; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopic Polyangiitis
Date of authorisation: 17/02/2017,, Revision: 19, Authorised, Last updated: 31/01/2023
-
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015
CHMP, Last updated: 26/06/2015auto-injectors INN adrenaline (epinephrine) More information Better … -
List item
Human medicine European public assessment report (EPAR): Upstaza
Eladocagene exuparvovec, Amino Acid Metabolism, Inborn Errors
Date of authorisation: 18/07/2022,, 
, 
, Revision: 2, Authorised, Last updated: 30/09/2022
-
List item
Human medicine European public assessment report (EPAR): Veyvondi (updated)
vonicog alfa, von Willebrand Diseases
Date of authorisation: 31/08/2018,, Revision: 6, Authorised, Last updated: 06/03/2023
-
List item
Human medicine European public assessment report (EPAR): Regkirona
Regdanvimab, COVID-19 virus infection
Date of authorisation: 12/11/2021,, Revision: 6, Authorised, Last updated: 12/12/2022
-
List item
Human medicine European public assessment report (EPAR): Sycrest
asenapine (as maleate) , Bipolar Disorder
Date of authorisation: 01/09/2010, Revision: 21, Authorised, Last updated: 07/12/2022 -
List item
Human medicine European public assessment report (EPAR): Lacosamide UCB
lacosamide, Epilepsies, Partial
Date of authorisation: 26/08/2019, Revision: 5, Authorised, Last updated: 25/01/2023 -
List item
Human medicine European public assessment report (EPAR): Entyvio (updated)
vedolizumab, Colitis, Ulcerative; Crohn Disease
Date of authorisation: 22/05/2014, Revision: 23, Authorised, Last updated: 01/03/2023 -
List item
Human medicine European public assessment report (EPAR): Olumiant (updated)
baricitinib, Arthritis, Rheumatoid
Date of authorisation: 13/02/2017,
, Revision: 10, Authorised, Last updated: 22/02/2023
-
List item
Human medicine European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos)
daunorubicin hydrochloride, cytarabine, Leukemia, Myeloid, Acute
Date of authorisation: 23/08/2018,, Revision: 8, Authorised, Last updated: 10/11/2022
-
List item
Human medicine European public assessment report (EPAR): Nuceiva
Botulinum toxin type A, Skin Aging
Date of authorisation: 27/09/2019,, Revision: 4, Authorised, Last updated: 10/06/2022
injection of botulinum toxin. Epinephrine (adrenaline) or any other … -
List item
Human medicine European public assessment report (EPAR): Skyrizi
Risankizumab, Psoriasis; Arthritis, Psoriatic
Date of authorisation: 26/04/2019,, Revision: 14, Authorised, Last updated: 17/01/2023
-
List item
Human medicine European public assessment report (EPAR): Nexavar
sorafenib, Carcinoma, Hepatocellular; Carcinoma, Renal Cell
Date of authorisation: 19/07/2006,, Revision: 32, Authorised, Last updated: 06/12/2022
-
List item
Human medicine European public assessment report (EPAR): Vyepti
eptinezumab, Migraine Disorders
Date of authorisation: 24/01/2022, Revision: 2, Authorised, Last updated: 29/11/2022 -
List item
Human medicine European public assessment report (EPAR): Recarbrio
imipenem monohydrate, cilastatin sodium, relebactam monohydrate, Gram-Negative Bacterial Infections
Date of authorisation: 13/02/2020,, Revision: 5, Authorised, Last updated: 29/11/2022
-
List item
Human medicine European public assessment report (EPAR): Azopt
brinzolamide, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 09/03/2000, Revision: 26, Authorised, Last updated: 11/07/2022 -
List item
Human medicine European public assessment report (EPAR): Suliqua
insulin glargine, lixisenatide, Diabetes Mellitus, Type 2
Date of authorisation: 11/01/2017, Revision: 9, Authorised, Last updated: 05/09/2022 -
List item
Human medicine European public assessment report (EPAR): Myozyme
alglucosidase alfa, Glycogen Storage Disease Type II
Date of authorisation: 28/03/2006, Revision: 22, Authorised, Last updated: 15/11/2022 -
List item
Human medicine European public assessment report (EPAR): Rapiscan
regadenoson, Myocardial Perfusion Imaging
Date of authorisation: 06/09/2010, Revision: 14, Authorised, Last updated: 30/06/2022 -
List item
Human medicine European public assessment report (EPAR): Insulin aspart Sanofi
insulin aspart, Diabetes Mellitus
Date of authorisation: 25/06/2020,, Revision: 3, Authorised, Last updated: 27/01/2022
-
List item
Human medicine European public assessment report (EPAR): Ganfort
bimatoprost, timolol, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 19/05/2006, Revision: 23, Authorised, Last updated: 20/07/2022 -
List item
Human medicine European public assessment report (EPAR): Xevudy
Sotrovimab, COVID-19 virus infection
Date of authorisation: 17/12/2021,, Revision: 7, Authorised, Last updated: 12/01/2023